Clinical Outcome of Tertiary Surgical Cytoreduction in Patients with Recurrent Epithelial Ovarian Cancer
| Autor: | Christina Fotopoulou, Werner Lichtenegger, Jalid Sehouli, Ioana Braicu, Peter Neuhaus, S. C. Schmidt, Rolf Richter |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
medicine.medical_specialty Neoplasm Residual Logistic regression Gastroenterology Young Adult Surgical oncology Internal medicine Ascites Humans Medicine Neoplasm Invasiveness Stage (cooking) Peritoneal Neoplasms Aged Aged 80 and over Ovarian Neoplasms business.industry Proportional hazards model Hazard ratio Middle Aged Adenocarcinoma Mucinous Carcinoma Papillary Confidence interval Endometrial Neoplasms Surgery Survival Rate Serous fluid Treatment Outcome Oncology Female Neoplasm Recurrence Local medicine.symptom business Adenocarcinoma Clear Cell Follow-Up Studies |
| Zdroj: | Annals of Surgical Oncology. 18:49-57 |
| ISSN: | 1534-4681 1068-9265 |
| DOI: | 10.1245/s10434-010-1245-3 |
| Popis: | The value of tertiary cytoreductive surgery (TCS) on overall survival (OS) of patients with relapsed epithelial ovarian cancer (ROC) is not well defined. Aim of the present study was to evaluate the operative and clinical outcome after TCS. We systematically evaluated all consecutive patients undergoing TCS. Tumor dissemination pattern, operative morbidity, residual tumor, and survival are described based on a validated intraoperative documentation tool. Predictors of survival and complete tumor resection are analyzed with Cox regression or logistic regression models. Between October 2000 and December 2008, 135 patients (median age, 51 years; range, 22–80 years) of mainly initial FIGO stage ≥III (106 patients, 78.5%) were evaluated. In 53 patients (39.3%) a complete tumor-resection was obtained. The 1-month operative mortality was 6%. During a median follow-up period of 9.6 months (range, 0.1–75 months), 78 patients (57.8%) died, while 52 patients (38.5%) experienced a further relapse. Median OS was 19.1 months for the total collective (95% confidence interval [95% CI], 14.84–23.35). Median OS was 37.8 months (95% CI, 12.7–62.7) for patients without residual tumor; versus 19.0 months (95% CI, 9.8–28.2) for residual tumor ≤1 cm and 6.9 months (95% CI, 3.05–10.7) for residual tumor >1 cm (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink